Monitor for any follow-up disclosures on committee assignments or strategic input from the new director, but expect minimal near-term impact on operations or valuation given the routine nature of this board transition.
Price Chart
Executive Summary
Rhythm Pharmaceuticals announced the appointment of Kimberly Popovits to its Board of Directors and the resignation of Edward T. Mathers, effective April 1, 2026. The changes reflect a routine board transition, with Popovits bringing extensive biopharma leadership experience and Mathers departing amicably after years of service.
Key Facts
- Kimberly J. Popovits appointed to the Board of Directors effective April 1, 2026, as a Class II director
- Edward T. Mathers resigned from the Board effective April 1, 2026, with no disagreement with the company
- Popovits has prior leadership experience as CEO of Genomic Health and senior roles at Genentech
- No financial terms, compensation changes, or strategic shifts were disclosed in connection with the board changes
Financial Impact
No direct financial impact disclosed
Risk Factors
- Potential shift in board dynamics or strategic oversight over time with new director
- Loss of long-tenured director's institutional knowledge, though departure was amicable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-023606 |
| Document: 0001628280-26-023606-index.html | 0001628280-26-023606 |
| Document: 0001628280-26-023606.txt | 0001628280-26-023606 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 144 | $96.77 $99.27 | ▼ −2.58% | ▼ −0.47% | $93.68 (+3.19%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▲ +1.65% | ▲ +1.45% | $93.68 (+18.72%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▼ −1.65% | ▼ −1.45% | $93.68 (−18.72%) |
Aug 4, 2026 8w ago | 8-K | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Aug 4, 2026 8w ago | Press Release | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Jul 8, 2026 12w ago | Press Release | $115.48 $106.09 | ▼ −8.13% | ▼ −8.00% | $93.68 (−18.88%) |
Jun 22, 2026 14w ago | 144 | $106.19 $110.04 | ▲ +3.63% | ▲ +2.61% | $93.68 (−11.78%) |
Jun 15, 2026 15w ago | 8-K | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 15, 2026 15w ago | Press Release | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 13, 2026 15w ago | Press Release | $89.70 $101.39 | ▲ +13.03% | ▲ +14.42% | $93.68 (+4.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access